Protara Therapeutics, Inc.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its pipeline includes TARA-002, an investigational cell therapy being developed for non-muscle invasive bladder cancer and lymphatic malformations. The company is also developing intravenous choline chloride, a phospholipid substrate replacement therapy intended for adolescent and adult patients dependent on parenteral support when oral or enteral nutrition is not possible, insufficient, or contraindicated. Its intended customer base comprises patients with these oncologic and rare disease conditions who have limited treatment options.

The company operates primarily in the United States and has clinical trials and studies spanning the United States, the United Kingdom, and Europe. It holds worldwide development and commercialization rights to TARA-002, excluding Japan and Taiwan. Protara Therapeutics maintains its corporate headquarters at 345 Park Avenue South in New York, New York.

Summary of the business section of Protara Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“we had 51 employees, 46 of whom were full-time employees and five of whom were temporary employees.”